SecBot SecBot

NKTX

Nkarta, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001787400 Biotech & Drug Discovery
$1.21 +0.02 (+1.68%)
Nov 16 4:00 PM ET · prev $1.19
Market cap
$90.7M
Micro cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$11.00
+809% · range $9.00–12.00
1 year
−33.1%
from $1.81 · Nov 17
30 days
−30.9%
from $1.75
52-week range
$1.19–3.67
−67% from high · low Nov 13
Avg volume 20D
1.70M
Nov 9 spike 9.30M
Short interest
3.84M
≈5.3% of shares · +12.1%
Days to cover
2.9
at average volume
Insider net
−$4.8K
0 buyers · 1 seller · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read BULLISH 5 reports · 90 days
Balance 1 bearish · 2 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 4/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $4.8K.

  • InstitutionsMIXED

    Q3 2026: 18 added (0 new), 16 trimmed or exited.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.380 → −$0.455 over 90 days.

  • Short sellersSTEADY

    Short interest +12.1% to 3.84M shares. 2.9 days to cover, ≈5.3% of shares.

  • TrendDOWNTREND

    44% below its 50-day average. New closing low $1.19 on Nov 13.

  • SocialQUIET

    No Reddit mentions this week. Last mention Oct 30.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCTRIM799,319$2.1M
MORGAN STANLEYADD349,922$916.8K
Qube Research & Technologies LtdADD194,977$510.8K
LOS ANGELES CAPITAL MANAGEMENT LLCDOUBLED142,653$373.8K
Nuveen, LLCTRIM124,689$326.7K
Empowered Funds, LLCADD108,165$283.4K
SEI INVESTMENTS COADD73,565$192.7K
IEQ CAPITAL, LLCTRIM62,934$164.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy4Buy8Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +809%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 9, 2026Needham
REITERATE
REITERATEBuy
Aug 14, 2026Stifel
MAINTAIN
MAINTAINBuy
Aug 11, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Reddit
Recent posts
All social signals and their track records

Insider ledger

Form 4
$0
bought · 0 insiders
$4.8K
sold · 1 insider
DateInsiderTypeValue
Jun 18, 2026
HASTINGS PAUL J
Chief Executive Officer
Jun 18, 2026
SELL$4.8K
Jun 10, 2026
Thedinga Angela
Director
Jun 10, 2026
AWARD37,000 sh
Jun 10, 2026
PATTERSON LEONE D
Director
Jun 10, 2026
AWARD37,000 sh
Jun 10, 2026
Dybbs Michael
Director
Jun 10, 2026
AWARD37,000 sh
Jun 10, 2026
Scheiner Zachary
Director
Jun 10, 2026
AWARD37,000 sh
Jun 10, 2026
Vratsanos George
Director
Jun 10, 2026
AWARD37,000 sh
Jun 10, 2026
George Simeon
Director
Jun 10, 2026
AWARD37,000 sh
Jun 10, 2026
Behbahani Ali
Director
Jun 10, 2026
AWARD37,000 sh

Earnings setup

Estimates
−$0.46
EPS estimate, this quarter
−20%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.46-$0.48–-$0.43-13.7%$0.00
Next Q-$0.42-$0.42–-$0.42-16.7%$0.00
Current FY-$1.82-$1.84–-$1.81-6.9%$0.00
Next FY-$1.51-$1.72–-$1.27+13.7%$0.00

Short side

FINRA· Oct 30, 2026
3,839,406
shares short
+12.1%
vs prior settlement
2.9
days to cover
≈5.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 11, 2026
Earnings date
NKTX Q3 2026 Earnings Scheduled · 2026-11-11
Nov 9, 2026
FDA
Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Nkarta (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered…
Nov 6, 2026
Company news
Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing…
Nov 5, 2026
Earnings
Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing…
Sep 8, 2026
Press release
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing…

SecBot reports

10 filings · 3 press releases · 2 bullish · 5 bearish · 3 neutral
All NKTX filing & press-release reports (13)